Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28402032 | 0.93 | MEN1 (0.32) | ELANE | |
| SCHEMBL20908295 | 0.93 | MEN1 (0.32) | ELANE | |
| SCHEMBL29640278 | 0.93 | MEN1 (0.32) | ELANE | |
| SCHEMBL21148892 | 0.88 | ELANE (0.33) | ELANE | |
| SCHEMBL28402063 | 0.88 | ELANE (0.33) | ELANE | |
| SCHEMBL21112505 | 0.86 | TACR3 (0.33) | ELANE | |
| SCHEMBL21112509 | 0.86 | TACR3 (0.33) | ELANE | |
| SCHEMBL23114827 | 0.84 | CTSS (0.33) | — | |
| SCHEMBL20908278 | 0.84 | CTSS (0.33) | — | |
| SCHEMBL20907707 | 0.81 | CYP2C9 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2019075291-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | ELANE 176/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | ELANE 176/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | ELANE 176/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | ELANE 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.